<DOC>
	<DOCNO>NCT01535183</DOCNO>
	<brief_summary>The outcome pediatric refractory relapse brain tumor dismal . Standard chemotherapy show poor response patient . Although tandem high dose chemotherapy hematopoietic progenitor stem cell rescue choose potentially curative therapy long term survival well outcome expect tumor burden transplantation reduce chemotherapy , effective salvage chemotherapy tumor reduction establish yet . Irinotecan recently develop topoisomerase I inhibitor , preclinical phase I , II data prove practical effect brain tumor . In study , irinotecan administer alone combination one drug . Vincristine , etoposide , carboplatin , cyclophosphamide use many protocol brain tumor result poor refractory relapse case . However , irinotecan effective multiple chemotherapeutic agent . According pilot study irinotecan combination vincristine , etoposide , carboplatin cyclophosphamide investigator center , 75 % percent total 12 patient reach stable disease , 2 patient get long term complete remission multi-agent combination chemotherapy . But combination irinotecan , vincristine , etoposide , carboplatin , cyclophosphamide clinically study yet especially pediatric patient . To improve response rate progression-free survival , combination chemotherapy irinotecan , vincristine , etoposide , carboplatin , cyclophosphamide design pediatric refractory relapse brain tumor .</brief_summary>
	<brief_title>Irinotecan Combination Chemotherapy Refractory Relapsed Brain Tumor Children Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Diagnosis brain tumor : embryonal brain tumor ( medulloblastoma , CNS PNET , ATRT , etc ) , intracranial germ cell tumor Relapse refractory state Prior therapy : Patients must fully recover acute toxic effect prior chemotherapy , immunotherapy , radiotherapy prior enter study . Patients eligible 8 week day stem cell infusion autologous stem cell transplant , hematological eligibility criterion meet . Performance status : ECOG 02 . Patients must free significant functional deficit major organ , follow eligibility criterion may modify individual case . 1 . Heart : shortening fraction ≥ 28 % 2 . Liver : total bilirubin &lt; 2 × upper limit normal ; ALT &lt; 3 × upper limit normal . 3 . Kidney : creatinine &lt; 2 × normal Patients must lack active viral infection active fungal infection . Patients ( one parent patient age &lt; 20 ) sign inform consent . Pregnant nursing woman . Malignant ( except brain tumor ) nonmalignant illness uncontrolled whose control may jeopardize complication study therapy . Psychiatric disorder would preclude compliance . Patients , opinion investigator , may able comply safety monitoring requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>irinotecan</keyword>
	<keyword>brain tumor</keyword>
	<keyword>pediatrics</keyword>
	<keyword>salvage therapy</keyword>
	<keyword>chemotherapy</keyword>
</DOC>